Novartis Dives Into In Vivo Gene-Editing With Precision Biosciences Deal
Could Challenge Bluebird and CRISPR/Vertex Ex Vivo Approaches
Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.
